Xeris Biopharma Holdings, Inc. XERS
9.10
0.15
1.68%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow XERS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 118.22% | (108.59%) | (6.96%) | 107.18% |
+8 more TTM periods Free account |
|
| (4.60%) | 3.39% | 0.16% | (4.52%) | ||
ROIC |
18.88% | 18.32% | 12.65% | 4.82% | |
Return on Tangible Assets |
(19.07%) | 8.69% | 0.41% | (13.87%) | |
Average Days of Receivables |
63.23 | 65.26 | 63.85 | 73.72 | |
Free Cash Flow per Share |
0.32 | 0.28 | 0.17 | 0.06 | |
Free Cash Flow |
55.67 | 47.52 | 27.93 | 9.98 | |
Capital Expenditures |
(0.94) | (1.01) | (0.70) | (0.58) | |
Piotroski F-Score |
6.00 | 8.00 | 8.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
15.53% | 14.03% | 8.30% | 3.40% | |
Accounts Receivable Turnover |
6.04 | 6.14 | 6.38 | 5.61 | |
Accounts Payable Turnover |
4.79 | 4.99 | 15.87 | 5.88 | |
Inventory Turnover |
0.61 | 0.70 | 0.73 | 0.73 | |
Average Days of Payables |
75.68 | 94.24 | 26.37 | 57.96 | |
Days of Inventory on Hand |
656.01 | 610.05 | 588.82 | 599.12 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.38% | 10.23% | 10.68% | 11.04% | |
Selling, General and Administrative Expense of Revenue |
62.05% | 60.82% | 62.49% | 65.76% | |
Share Based Compensation of Revenue |
8.38% | 7.01% | 7.66% | 7.77% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(3.30) | 4.04 | 51.67 | (0.68) | |
Depreciation/Fixed assets |
3.37 | 3.21 | 3.25 | 3.23 | |
Capex/Depreciation |
(0.06) | (0.06) | (0.04) | (0.04) | |
Revenue per Share |
1.94 | 1.85 | 1.82 | 1.63 | |
Operating CF per Share |
0.33 | 0.28 | 0.18 | 0.06 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(5.12%) | 3.81% | 0.19% | (5.88%) |
Columns are period end dates